Exploring KRAS-mutant pancreatic ductal adenocarcinoma: a model validation study

Area of Science:

• Oncology
• Genomics
• Bioinformatics

Background:

• Pancreatic ductal adenocarcinoma (PDAC) has a high mortality rate, with KRAS mutations frequently promoting tumorigenesis.
• Understanding KRAS mutation interactions is crucial for developing effective therapeutic strategies against PDAC.

Purpose of the Study:

• To establish and validate a prediction model for KRAS mutations in PDAC patients using survival analysis and mRNA expression.
• To identify differential biological pathways and potential therapeutic targets associated with KRAS mutation status in PDAC.

Main Methods:

• Utilized The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) databases (184 and 412 PDAC patients, respectively).
• Performed tumor mutation profile, copy number variation (CNV) analysis, survival analysis, and mRNA expression profiling.
• Employed principal component analysis, pathway enrichment, Gene Ontology (GO), and gene set enrichment analysis (GSEA) for pathway analysis.

Main Results:

• A seven-gene prediction model (CSTF2, FAF2, KIF20B, AKR1A1, APOM, KRT6C, CD70) was established and validated, showing good predictive ability for overall survival (OS) in KRAS-mutated PDAC.
• Identified significant pathway enrichments including cytokine-cytokine receptor interaction and metabolism of xenobiotics, with numerous downregulated metabolic pathways in the high-risk group.
• Correlations between risk score and tumor immune infiltration (neutrophils, CD4 memory T cells, NK cells) were observed; potential drugs were screened.

Conclusions:

• A validated model for predicting PDAC prognosis based on KRAS mutation status was developed.
• Differential pathways, including metabolic and immune-related pathways, were identified, offering insights into PDAC progression.
• The study identified potential therapeutic drugs linked to the risk score, paving the way for targeted treatments.